The webinar series will include a live question-and-answer session with Pfizer medical experts.
We are hosting Translating mRNA sessions on the topics below.
1. Select Bivalent COVID-19 Vaccine Information Presented at Recent FDA Advisory Committee Meeting
Speaker: Rajeev M Nepal, PhD
Medical Director, Pfizer mRNA Vaccines, Medical and Scientific Affairs, USA
2. COVID-19 Vaccination: Considerations for Pediatric Patients
Speaker: Maria D. McColgan, MD, MSEd
Medical Director, Pfizer mRNA Vaccines, Medical and Scientific Affairs, USA
Click here to Register https://www.translatingmrna.com/
Continuing medical education credit is NOT associated with this event.
Emergency uses of the vaccines have not been approved or licensed by the US Food and Drug Administration (FDA) but have been authorized by the FDA under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
For more information, please see the full Prescribing Information and EUA Fact Sheets for Vaccination Providers Click here.
